Clinical Trials Browser

Approved for marketing × Neoplasms × tovorafenib × Clear all

NCT05760586 2024-08-12

Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Approved for marketing

Glioma, Neoplasms